Search
Obeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigationalPrimary biliary cirrhosis, or PBC, is a progressive and chronic condition that leads to hepatic injury often resulting in end-stage liver failure that requires liver transplantation. … The NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected to be granted full approval for this indication in 2020.[L12636]
Besilesomab
go.drugbank.com/drugs/DB13979ApprovedBesilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis … Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the
Isatuximab
go.drugbank.com/drugs/DB14811ApprovedInvestigational[L12099] It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma. … Following three consecutive years on the yearly "Antibodies to watch" list published in "mAb", a peer-reviewed scientific journal dedicated to antibody research,[A38676,A191826,A191829] isatuximab was
Netupitant
go.drugbank.com/drugs/DB09048ApprovedInvestigationalNetupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy
Synonyms: 2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamideRitlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigationalIn June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further approved by the EMA in September 2023. … [A260122,A260127] Other kinases have a cysteine at a position equivalent to Cys-909 in JAK3, and several of them belong to the TEC kinase family.
Inebilizumab
go.drugbank.com/drugs/DB12530ApprovedInvestigational[L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838] … Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD.
Ferric cation
go.drugbank.com/drugs/DB13949ApprovedWithdrawnIron is an essential element involved in various metabolic processes, including oxygen transport, deoxyribonucleic acid (DNA) synthesis, and energy production in electron transport [A32514]. … Non-haem iron in food is mainly in the ferric state, which is the insoluble form of iron, and must be reduced to the ferrous cation for absorption [T28].
Mixtures: FERRITIN COMPLEXLiothyronine
go.drugbank.com/drugs/DB00279ApprovedInvestigationalVet approvedLiothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. … [T457] The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.[L5578]
L-Glutamine
go.drugbank.com/drugs/DB00130ApprovedInvestigationalNutraceuticalAn oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical. … It is the principal carrier of nitrogen in the body and is an important energy source for many cells.
Temsirolimus
go.drugbank.com/drugs/DB06287ApprovedInvestigationalTemsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007. … Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel.